Oral oleoyl-estrone induces the rapid loss of body fat in Zucker lean rats fed a hyperlipidic diet.
OBJECTIVE
To test whether oleoyl-estrone affects body weight when given orally, which may help curtail the secondary growth-boosting effects of derived estrone.


METHODS
The rats were fed for 15 days with a powdered hyperlipidic diet (16.97 MJ/kg metabolizable energy) in which 46.6% was lipid-derived and 16.1% protein-derived energy (HL group), containing 1.23+/-0.39micromol/kg of fatty-acyl esters of estrone. This diet was supplemented with additional oleoyl-estrone to produce diets with 2.5 micromol/kg (diet OE2.5), 4.4 micromol/kg (diet OE4.4), and 33.3 micromol/kg content in fatty-acyl estrone (diet OE33).


METHODS
Twelve-week old female Zucker lean (Fa/?) rats initially weighing 200-235g.


METHODS
Food intake and body weight changes; urine and droppings production and nitrogen content. Body composition (water, lipid, protein) and total energy. Energy and nitrogen balances. Plasma chemistry including free amino acids.


RESULTS
Oral administration of oleoyl-estrone in a hyperlipidic diet resulted in significant losses of fat, energy and, ultimately, weight, which were dependent on the dose of oleoyl-estrone ingested. Treatment induced the maintenance of energy expenditure combined with lower food intake, creating an energy gap that was filled with internal fat stores whilst preserving body protein. The decrease in food intake was not a consequence of food aversion but of diminished appetite. Energy expenditure was practically constant for all groups except for the OE33, which showed values about 25% lower than the controls. In most of the groups studied, there was a net protein deposition in spite of severe lipid and energy drainage. Amino acid levels agreed with this N-sparing shift. In spite of lowered energy intake, the N balance was positive or near zero in all groups, with a sizeable N-gap in controls and in lower-dose groups that disappeared in the OE33 group.


CONCLUSIONS
Treatment of rats with a hyperlipidic diet containing added oleoyl-estrone resulted in the dose-related loss of fat reserves with scant modification of other metabolic parameters and preservation of body protein. The results agree with the postulated role of oleoyl-estrone as a ponderostat signal and open the way for its development as anti-obesity drug.
Remesar
X
X
Centre de Recerca en Nutrició i Ciència dels Aliments, Universitat de Barcelona, Spain.
Guijarro
P
P
Torregrosa
C
C
Grasa
M M
MM
López
J
J
Fernández-López
J A
JA
Alemany
M
M
D000273:Adipose Tissue / Q000187:drug effects; D000284:Administration, Oral; D000596:Amino Acids / Q000097:blood; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001823:Body Composition / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D004032:Diet / Q000009:adverse effects; D004041:Dietary Fats / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D002149:Energy Intake / Q000187:drug effects; D004734:Energy Metabolism / Q000187:drug effects; D004970:Estrone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D009584:Nitrogen / Q000378:metabolism; D009765:Obesity / Q000188:drug therapy* / Q000378:metabolism; D009829:Oleic Acids / Q000008:administration & dosage / Q000494:pharmacology*; D011506:Proteins / Q000378:metabolism; D051381:Rats; D011924:Rats, Zucker; D013997:Time Factors
D000596:Amino Acids; D019440:Anti-Obesity Agents; D004041:Dietary Fats; D009829:Oleic Acids; D011506:Proteins; D004970:Estrone; C108709:oleoyl-estrone; D009584:Nitrogen